Results 111 to 120 of about 51,607 (296)

Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial

American journal of hematology/oncology, 2018
The aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab‐Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first‐line therapy in CD33 positive AML. We treated 130 patients,
A. Candoni, C. Papayannidis, G. Martinelli, E. Simeone, M. Gottardi, I. Iacobucci, F. Gherlinzoni, G. Visani, M. Baccarani, R. Fanin   +9 more
semanticscholar   +1 more source

Long-Term Skin Allograft Survival Elicited by a Finite Treatment with Antilymphocyte Serum Combined with Cytarabine [PDF]

, 1970
R. J. Perper, R. E. Monovich, B. E. Bowersox   +2 more
openalex   +1 more source

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

Blood, 2018
Background: ALRN-6924, the first-ever clinical stage stapled peptide, has been structurally stabilized ("stapled") in an α-helical configuration, to mimic the inhibitor-binding region of the intracellular tumor suppressor protein, p53.
D. Sallman, U. Borate, E. Cull, W. Donnellan, R. Komrokji, U. Steidl, M. Corvez, M. Payton, D. A. Annis, D. Pinchasik, M. Aivado, A. Verma   +11 more
semanticscholar   +1 more source

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

Internal Medicine Journal, EarlyView.
Abstract Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline ...
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, George Grigoriadis, Shaun Fleming, Shahla Vilcassim, Pasquale L. Fedele, Michael Sze Yuan Low, Paul Yeh, Michael Gilbertson, Ashwini Bennett, Gareth P. Gregory, Danielle Oh, Donna Gairns, Zane Kaplan, Sanjeev D. Chunilal, Susan Brown, Stephen Opat, Chong C. Chua, Jake Shortt   +19 more
wiley   +1 more source

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Annals of Oncology, 2018
Background The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML).
Christoph Röllig, Michael Kramer, M. Gabrecht, M. Gabrecht, M. Hänel, R. Herbst, Ulrich Kaiser, Norbert Schmitz, J. Kullmer, S. Fetscher, Hartmut Link, L. Mantovani-Löffler, U. Krümpelmann, T. Neuhaus, F. Heits, H. Einsele, B. Ritter, M. Bornhäuser, J. Schetelig, Christian Thiede, B. Mohr, M. Schaich, U. Platzbecker, K. Schäfer-Eckart, Alwin Krämer, We Berdel, H. Serve, G. Ehninger, Ulrich Schuler   +28 more
semanticscholar   +1 more source

Exploring the Influence of Oral and Gut Microbiota on Ulcerative Mucositis: A Pilot Cohort Study

Oral Diseases, EarlyView.
ABSTRACT Aim Comparing oral and gut microbiome profiles between patients with and without ulcerative mucositis during allogeneic stem cell transplantation (aSCT). Materials and Methods Specimens from oral mucosa, saliva, and stool were collected pre‐(T0) and post‐ (T0 +28d ± 14d) aSCT (T1).
Valentin Bartha, Sébastien Boutin, Dorothée L. Schüßler, Anna Felten, Shila Fazeli, Florentina Kosely, Thomas Luft, Diana Wolff, Cornelia Frese, Kyrill Schoilew   +9 more
wiley   +1 more source

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults [PDF]

, 1988
Arlin Za, Eric J. Feldman, Sanford Kempin, Tauseef Ahmed, Abraham Mittelman, S. Savona, Joad L. Ascensao, Paul Baskind, Phyllis Sullivan, HG Fuhr   +9 more
openalex   +1 more source

Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation [PDF]

, 1988
Walter Gassmann, L. Uharek, H-U. Wottge, Norbert Schmitz, H. Löffler, W Mueller-Ruchholtz   +5 more
openalex   +1 more source

Advancements in genetic analysis: Insights from a case study and review of next‐generation sequencing techniques for veterinary oncology applications

Veterinary Clinical Pathology, EarlyView.
Abstract Acute myeloid leukemia (AML) poses significant challenges in veterinary medicine, with limited treatment options and poor survival rates. While substantial progress has been made in characterizing human AML, translating these advancements to veterinary practice has been hindered by limited molecular understanding and diagnostic tools. The case
R. Adam Harris, Jillian Nolan, Dylan Ammons, Samantha Beeson, Douglas Thamm, Anne Avery   +5 more
wiley   +1 more source

Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes

ClinicoEconomics and Outcomes Research, 2022
Kwanza Price,1 Zhun Cao,2 Craig Lipkin,2 Deb Profant,1 Scott Robinson2 1Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Premier Inc., Charlotte, NC, USACorrespondence: Deb ProfantJazz Pharmaceuticals, 3170 Porter Dr., Palo Alto, CA, 94304, USATel/Fax +1 971 ...
Price K, Cao Z, Lipkin C, Profant D, Robinson S   +4 more
doaj